Treatment of AL amyloid is directed at the expanded plasma cell clone. However, there are also now potential treatments on the horizon for TTR amyloid, currently being tested in trials (3, 4) . Hence, identification of the presence of cardiac amyloid and its specific etiology is assuming increasing importance.
The gold standard for diagnosis and assessment of specific amyloid subtype is obtaining tissue using endomyocardial biopsy. However, the expertise needed for this technique limits it to centers specializing in advanced heart failure. Thus, a non- he has no relationships relevant to the contents of this paper to disclose.
also studied with PET/CT 11 C-PiB imaging in an attempt to define a normal range.
Among the 15 patients with biopsy-proven cardiac amyloid (all with the AL type), the 11 C-PiB uptake relative to the blood cavity was higher than in those patients with negative biopsies. Figure 1 
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